Result of AGM
20 3월 2009 - 12:51AM
UK Regulatory
TIDMPYN
RNS Number : 1614P
Phynova Group PLC
19 March 2009
+-------------------------------------+-------------------------------------+
| | 19 March 2009 |
+-------------------------------------+-------------------------------------+
Phynova Group plc
("Phynova")
Annual General Meeting 2009
Phynova Group plc (AIM: PYN, OTCQX: PHNVY), the developer of prescription
pharmaceuticals derived from plants used in Chinese medicines, held its Annual
General Meeting at Phynova´s offices in Long Hanborough today. All resolutions
put to the shareholders, as set out in the notice of annual general meeting
dated 20 February 2009, were passed by the necessary majorities.
- Ends -
For further information, please contact:
+--------------------------------------------+----------------------------+
| Phynova Group PLC | +44 (0) 1993 880700 |
+--------------------------------------------+----------------------------+
| John Pool (Executive Chairman) | |
+--------------------------------------------+----------------------------+
| Tony Mills (CEO Phynova Limited) | |
+--------------------------------------------+----------------------------+
| Robert Miller (CEO Phynova China Limited) | |
+--------------------------------------------+----------------------------+
| | |
+--------------------------------------------+----------------------------+
| Nominated Adviser: | |
+--------------------------------------------+----------------------------+
| John East & Partners Limited | +44 (0) 20 7618 2200 |
+--------------------------------------------+----------------------------+
| Simon Clements | |
+--------------------------------------------+----------------------------+
| | |
+--------------------------------------------+----------------------------+
| Broker: | |
+--------------------------------------------+----------------------------+
| Evolution Securities China Limited | +44 (0) 20 7071 4389 |
+--------------------------------------------+----------------------------+
| Barry Saint | |
+--------------------------------------------+----------------------------+
Media enquiries:
+--------------------------------------------+----------------------------+
| Capital MS&L | +44 (0) 20 7307 5330 |
+--------------------------------------------+----------------------------+
| Mary Clark/Anna Mitchell | |
+--------------------------------------------+----------------------------+
| | |
+--------------------------------------------+----------------------------+
Notes to Editors:
About Phynova
Phynova is a UK company developing new prescription pharmaceuticals derived from
plants used in Chinese medicines. The Company is focused on viral and bacterial
diseases, metabolic diseases and cancer. Phynova's lead product for hepatitis C
has now completed a Phase I/II trial in the US. Two further products, for fatty
liver disease and post-operative ileus, are targeted for entry to the clinic and
there are a further four products in preclinical development.
For further information please visit www.phynova.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGJLMATMMIBBPL
Phynova (LSE:PYN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Phynova (LSE:PYN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
